Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04988997 · ClinicalTrials.gov registry record · Phase 2
VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.
A Phase 2 study, sponsored by 9 Meters Biopharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04988997: Clinical Trial Phase 2 study, sponsored by 9 Meters Biopharma.
NCT04988997 is a Phase 2 study that was terminated before completion, run by 9 Meters Biopharma. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04988997, a Phase 2 study, was terminated before completion, sponsored by 9 Meters Biopharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
A Study of Vurolenatide in Adult Patients with Short Bowel Syndrome.
Primary Outcome
The primary outcome measure is 24hr total stool output volume over the double-blind treatment period compared to baseline.
Interventions
- DRUG Placebo
- DRUG Vurolenatide 50mg/PBO
- DRUG Vurolenatide 100mg/PBO
- DRUG Vurolenatide 50/50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-06-14 |
| Est. Completion | 2022-08-24 |
| Phase | Phase 2 |
Why NCT04988997 stopped before completion
NCT04988997 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04988997 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04988997 about?
NCT04988997 is a clinical study titled "VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.". A Study of Vurolenatide in Adult Patients with Short Bowel Syndrome.
What is the current status of trial NCT04988997?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-06-14. Estimated completion is 2022-08-24.
What interventions are being tested in trial NCT04988997?
The interventions under investigation include: Placebo (DRUG), Vurolenatide 50mg/PBO (DRUG), Vurolenatide 100mg/PBO (DRUG), Vurolenatide 50/50 mg (DRUG).
Who is sponsoring clinical trial NCT04988997?
This trial is sponsored by 9 Meters Biopharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04988997's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI